Advertisement
JBC

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Originally published In Press as doi:10.1074/jbc.M410561200 on March 10, 2005 Originally published In Press as doi:10.1074/jbc.M410561200 on March 8, 2005

J. Biol. Chem., Vol. 280, Issue 19, 18579-18589, May 13, 2005
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Supplemental Data
Right arrow All Versions of this Article:
280/19/18579    most recent
M410561200v2
M410561200v1
Right arrow Submit a Letter to Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Roux, J.
Right arrow Articles by Pittet, J.-F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Roux, J.
Right arrow Articles by Pittet, J.-F.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Interleukin-1{beta} Decreases Expression of the Epithelial Sodium Channel {alpha}-Subunit in Alveolar Epithelial Cells via a p38 MAPK-dependent Signaling Pathway*{boxs}

Jérémie Roux{ddagger}§¶||**, Hisaaki Kawakatsu||{ddagger}{ddagger}, Brandi Gartland{ddagger}§¶||**, Melissa Pespeni{ddagger}§¶||**, Dean Sheppard||{ddagger}{ddagger}, Michael A. Matthay§||**, Cecilia M. Canessa§§, and Jean-François Pittet{ddagger}§¶||**¶¶

From the {ddagger}Laboratory of Surgical Research, the **Cardiovascular Research Institute, the {ddagger}{ddagger}Lung Biology Center, and the Departments of §Anesthesia, Surgery, and ||Medicine, University of California, San Francisco, California 94110 and the §§Department of Cellular and Molecular Physiology, Yale University School of Medicine, New Haven, Connecticut 06520

Received for publication, September 14, 2004 , and in revised form, February 23, 2005.


   ABSTRACT
TOP
 ABSTRACT
INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 
Acute lung injury (ALI) is a devastating syndrome characterized by diffuse alveolar damage, elevated airspace levels of pro-inflammatory cytokines, and flooding of the alveolar spaces with protein-rich edema fluid. Interleukin-1{beta} (IL-1{beta}) is one of the most biologically active cytokines in the distal airspaces of patients with ALI. IL-1{beta} has been shown to increase lung epithelial and endothelial permeability. In this study, we hypothesized that IL-1{beta} would decrease vectorial ion and water transport across the distal lung epithelium. Therefore, we measured the effects of IL-1{beta} on transepithelial current, resistance, and sodium transport in primary cultures of alveolar epithelial type II (ATII) cells. IL-1{beta} significantly reduced the amiloride-sensitive fraction of the transepithelial current and sodium transport across rat ATII cell monolayers. Moreover, IL-1{beta} decreased basal and dexamethasone-induced epithelial sodium channel {alpha}-subunit ({alpha}ENaC) mRNA levels and total and cell-surface protein expression. The inhibitory effect of IL-1{beta} on {alpha}ENaC expression was mediated by the activation of p38 MAPK in both rat and human ATII cells and was independent of the activation of {alpha}v{beta}6 integrin and transforming growth factor-{beta}. These results indicate that IL-1{beta} may contribute to alveolar edema in ALI by reducing distal lung epithelial sodium absorption. This reduction in ion and water transport across the lung epithelium is in large part due to a decrease in {alpha}ENaC expression through p38 MAPK-dependent inhibition of {alpha}ENaC promoter activity and to an alteration in ENaC trafficking to the apical membrane of ATII cells.


   INTRODUCTION
TOP
 ABSTRACT
 INTRODUCTION
EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 
Acute lung injury (ALI)1 is a devastating clinical syndrome manifested by diffuse alveolar damage, capillary injury, and disruption of the alveolar epithelium. The acute phase of ALI is characterized by the influx of protein-rich edema fluid that impairs gas exchange, causing arterial hypoxemia and respiratory failure with an overall mortality rate of 30–40% (1). Along with an increase in lung endothelial and epithelial permeability to protein, this syndrome is associated with abnormal surfactant production and decreased vectorial fluid transport across the lung epithelial barrier (2, 3). A number of inflammatory mediators have been found to be elevated in the alveolar space during the early phase of ALI, including interleukin (IL)-1{beta}, tumor necrosis factor-{alpha}, IL-6, and IL-8 (4). IL-1{beta} is one of the most biologically active cytokines in pulmonary edema and bronchoalveolar lavage fluids of patients with ALI (4–6). Indeed, IL-1{beta} increases microvascular lung epithelial permeability in in vitro and in vivo models of ALI (7). IL-1{beta} also enhances alveolar epithelial repair by increasing cell spreading (8) and fibroblast activation and proliferation (5). In contrast, the role of IL-1{beta} in distal lung epithelial ion transport remains unclear. In other epithelia such as the colonic epithelium, IL-1{beta} inhibits aldosterone-induced electrogenic sodium absorption and attenuates aldosterone-induced up-regulation of {beta}- and {gamma}-subunit mRNA expression (9). In the renal collecting duct, IL-1{beta} inhibits sodium absorption and stimulates anion secretion (10). Recently, IL-1{beta} has been shown to reduce amiloride-sensitive short circuit current (Isc) in normal human bronchial epithelial cells (11). However, the effect of IL-1{beta} on vectorial sodium transport across the alveolar lung epithelium is unknown.

We report here that IL-1{beta} inhibits alveolar epithelial sodium transport across the distal lung epithelium secondary to a reduction in epithelial sodium channel (ENaC) mRNA and protein expression in alveolar epithelial type II (ATII) cells. IL-1{beta} affects {alpha}ENaC transcription by inhibiting its promoter activity via a p38 MAPK-dependent mechanism, resulting in a decrease in the steady-state levels of both total and apical membrane {alpha}ENaC proteins.


   EXPERIMENTAL PROCEDURES
TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
RESULTS
 DISCUSSION
 REFERENCES
 
Reagents—All cell culture media were prepared by the University of California-San Francisco Cell Culture Facility using deionized water and analytical grade reagents. Amiloride, ouabain, decorin, and protease inhibitors were obtained from Sigma. Human recombinant IL-1{beta} and IL-1{beta} receptor antagonist (IL-1RA) were obtained from R&D Systems (Minneapolis, MN). 22Na+ was obtained from PerkinElmer Life Sciences. 32P and the chemiluminescence ECL Plus kit were obtained from Amersham Biosciences. Sulfosuccinimidyl 2-(biotinamido)-ethyl-1,3-dithiopropionate and streptavidin-agarose beads were obtained from Pierce. MAPK inhibitors PD98059 (an inhibitor of the kinase upstream of ERK1/2), SB202190 (an inhibitor of p38 MAPK), and SP600125 (a reversible inhibitor of JNK) were obtained from Calbiochem. These MAPK inhibitors have been shown to block their respective MAPKs in lung epithelial cells (12–15). Mifepristone (RU486), a known glucocorticoid receptor (GR) antagonist, was purchased from BIOMOL Research Labs Inc. (Plymouth Meeting, PA). Soluble chimeric transforming growth factor-{beta} (TGF-{beta}) type II receptor was purchased from Biogen Idec (Cambridge, MA). {alpha}v{beta}6 integrin-blocking antibody 10D5 originated in the laboratory of D. Sheppard (16). Polyclonal and affinity-purified {alpha}ENaC antibodies originated in the laboratory of B. C. Rossier (17). Antibodies and phospho-specific antibodies for p38 MAPK and MAPKAPK-2 were purchased from Cell Signaling Technology (Beverly, MA). Antibodies for Na+-K+-ATPase {alpha}1- and {beta}1-subunits were purchased from Upstate Biotechnology, Inc. (Charlottesville, VA). Horseradish peroxidase-conjugated goat anti-rabbit and anti-mouse secondary antibodies were purchased from ICN (Costa Mesa, CA). Cationic liposomes (FuGENE 6) were obtained from Roche Applied Science. The following two plasmids were a kind gift from André Dagenais (Université de Montreal, Montreal, Canada): plasmid pGL-3 containing the luciferase gene subcloned downstream of the full-length murine {alpha}ENaC promoter (pGL3-basic/{alpha}mENaC) and plasmid pGL-3 containing the luciferase gene subcloned downstream of the murine {alpha}ENaC promoter with a deletion in the glucocorticoid response element (GRE) (pGL3-basic/{alpha}mENaC{Delta}AVR-XhOI). The protein concentration of cell lysates was determined using a Bio-Rad protein assay kit or a BCA kit (Pierce).

Cell Culture—Primary cultures of rat and human alveolar epithelial cells were used for the in vitro studies. Rat ATII cells were isolated as described previously (18, 19) with slight modifications. Briefly, cells were isolated by elastase digestion, followed by negative selection using four monoclonal antibodies against cell-surface molecules expressed on rat macrophages (CD4, CD32, CD45, and rat macrophage activator) purchased from Pharmingen. These monoclonal antibodies were preincubated with Dynabeads M-450 (magnetic beads with sheep anti-mouse IgG; Dynal Biotech ASA, Oslo, Norway) in 0.1% bovine serum albumin in phosphate-buffered saline (PBS). After removing unbound monoclonal antibodies, rat ATII cells were mixed with the bead suspension and rocked gently for 30 min at 4 °C. Unbound cells were isolated and plated on polycarbonate Transwell dishes (0.4-µm pore size; Corning). Cells were seeded at a concentration of 1.5 x 106 cells/cm2 in Dulbecco's modified Eagle's medium/H21 medium containing 10% low endotoxin fetal bovine serum and 1% penicillin/streptomycin and kept at 37 °C in a humidified 95% air and 5% CO2 environment. Twenty-four hours later, non-adherent epithelial cells were removed by washing with PBS, and fresh medium was added to the lower compartments of the Transwell dishes, thus maintaining the ATII cell monolayers with an air-liquid interface on their apical side. After 72–96 h, cells that formed confluent monolayers reaching a transepithelial electrical resistance (TER) >1500 ohms/cm2 were used for experimentation.

Human ATII cells were isolated using a modification of the method described previously (20). Briefly, alveolar type II cells were isolated from human lungs that were not used by the Northern California Transplant Donor Network. Our studies indicated that these lungs were in good condition, both physiologically and pathologically (21). Cells were isolated after the lungs had been preserved for 4–8 h at 4 °C. A lobe of human lung that had no evidence of injury on the pre-harvest chest radiograph, that could be normally inflated, and that had no area of consolidation or hemorrhage was selected. The pulmonary artery for this segment was perfused with 37 °C PBS solution, and the distal airspaces of a segmental bronchus were lavaged 10 times with 37 °C Ca2+/Mg2+-free PBS solution containing 0.5 mM each EGTA and EDTA. Sixty to ninety milliliters of pancreatic porcine elastase (8 units/ml) diluted in Ca2+/Mg2+-free Hanks' balanced saline solution were instilled into the airspaces of 50 g of the chosen segment of lung tissue. The lung was incubated in a water bath for 30 min at 37 °C and minced finely in the presence of fetal bovine serum and DNase I (500 µg/ml). The cell-rich fraction was filtered sequentially through one- and two-layer gauze and 150- and 30-µm nylon mesh. The cell suspension was then layered onto a discontinuous Percoll density gradient (1.04–1.09 g/ml) and centrifuged at 400 x g for 20 min to remove red blood cells. The cells that accumulated at the interface of the solution and the Percoll were a mixture of type II pneumocytes and alveolar macrophages. These cells were recovered by centrifugation at 200 x g for 10 min at 4 °C. The pellet was resuspended in Dulbecco's modified Eagle's medium containing 10% fetal calf serum. The cells were incubated in Dulbecco's modified Eagle's medium containing magnetic beads coated with anti-CD14 antibody (Dynabeads M-450 CD14, Dynal Biotech ASA) at 4 °C for 40 min under constant mixing to eliminate macrophages. Cell viability was assessed by trypan blue exclusion. The purity of isolated human alveolar type II cells was checked by Papanicolaou staining or by staining with anti-human type II cell antibody (obtained from Leland Dobbs, University of California, San Francisco), and the purity was consistently >90% (data not shown). Human alveolar type II cells were seeded on collagen I-coated Transwell dishes at a density of 1 x 106 cells/cm2. Five days after the cells were seeded, the monolayer developed a TER >1500 ohms/cm2, as reported for rat ATII cell monolayers.

Cell Viability—Cell viability after exposure to different experimental conditions was measured by the Alamar Blue assay (22). Cell media were replaced with medium containing 10% Alamar Blue and placed at 37 °C in a cell incubator for 2–3 h. The media were then collected and read on a plate reader at 530 nm.

Measurement of Monolayer Bioelectric Properties—The TER (kilo-ohms/cm2) and potential difference (PD; millivolts, apical side as reference) were measured using the Millicell-ERS Voltohmmeter (Millipore Corp., Bedford, MA). Transepithelial current (Isc; microamps/cm2) was calculated from the relationship Isc = PD/Rt (Ohm's law). The effect of IL-1{beta} (10–3 to 10 ng/ml for 1–24 h) or its vehicle on the bioelectric properties of ATII cell monolayers was evaluated on day 4 in culture. IL-1{beta} was also added on the apical or basolateral side or on both sides of the cell monolayer.

Sodium Uptake Measurements—The activity of the sodium transport pathway on the apical membrane of rat ATII cells was determined by unidirectional tracer uptake measurements using the technique described by Mairbaurl et al. (23). Briefly, after exposure to IL-1{beta} or its vehicle on both sides of the Transwell, the cells were washed twice with wash medium (150 mM NaCl and 2 mM HEPES, pH 7.4) at 37 °C and equilibrated with flux medium (140 mM NaCl, 5 mM KCl, 1 mM Na2HPO4, 1 mM MgCl2, 0.2 mM CaCl2, 10 mM glucose, and 20 mM HEPES, pH 7.4) for 10 min at 37 °C. After equilibration, only the apical medium was replaced with fresh flux medium containing 22Na+ at a final activity of 5 µCi/ml and ouabain (3 mM). After 6 min, cell monolayers were washed three times by overflow with cold wash medium to eliminate 22Na+ not taken up by the cells and to stop further uptake. The last wash solution was measured for 22Na+ and verified not to contain any radioactivity. The cells were then lysed with 0.1% NaOH, and the radioactivity in the lysate was measured in a {beta}-counter. Protein determination was used for normalization of the results. Control experiments showed that the tracer uptake was linear over a range of 10 min. Thus, only one 6-min time point was taken. All fluxes were measured in triplicate.

Transepithelial Sodium Transport Measurements—The activity of the amiloride-sensitive sodium transport pathway across rat ATII cell monolayers was determined by unidirectional tracer transport measurements adapted from the technique described by Mairbaurl et al. (23). Briefly, after exposure to IL-1{beta} or its vehicle on both sides of the Transwell, the cells were washed twice with wash medium at 37 °C and equilibrated with flux medium for 10 min at 37 °C. After equilibration, only the apical medium was replaced with fresh flux medium containing 22Na+ at a final activity of 5 µCi/ml. After 10 min, the basolateral medium was obtained, and the radioactivity was measured in a {beta}-counter. The cells were then lysed with 0.1% NaOH, and the protein concentration was determined for normalization of the results. All fluxes were measured in triplicate.

Western Blot Analysis—Western blot analysis was performed as described previously (24). After equal amounts of protein were loaded on each lane and separated by 10% SDS-PAGE, proteins were transferred to Immobilon-P membranes (Millipore Corp.), and {alpha}ENaC was detected using an affinity-purified antibody at 1:1000 dilution and horseradish peroxidase-conjugated goat anti-rabbit antibody at 1:10,000 dilution. Anti-p38 MAPK and anti-phospho-p38 MAPK antibodies were used at 1:500 dilution, and horseradish peroxidase-conjugated goat anti-mouse and anti-rabbit antibodies were used at 1:5000 dilution. The protein bands were visualized by chemiluminescence. Quantification was done using a ChemiImager digital image analysis system (Alpha Innotech, San Leandro, CA).

Membrane Protein Biotinylation—Biotinylation and recovery of apical membrane proteins were performed as described previously (25) using sulfosuccinimidyl 2-(biotinamido)-ethyl-1,3-dithiopropionate. The protein concentration of the lysates was determined using the BCA kit. Streptavidin-agarose beads were added to equal amounts of total protein to recover the biotinylated proteins. The amount of added beads was adjusted to ensure complete recovery of biotinylated proteins from lysates. Biotinylated proteins were eluted from the beads by heating to 90 °C in SDS-PAGE sample buffer and analyzed by Western blotting. Actin, a cytoskeletal protein, was used as a control for the specificity of surface biotinylation. This protein was detected in cell lysates, but not in the pool of protein recovered after apical surface biotinylation.

{alpha}ENaC Promoter Reporter Cells and Luciferase Assay—Rat ATII cells were transiently transfected with the pGL3-basic/{alpha}mENaC or pGL3-basic/{alpha}mENaC{Delta}AVR-XhOI plasmid. After rat ATII cells were plated on Transwell dishes (5 x 105 cells/Transwell) and grown in an air-liquid interface for 24 h, they were transfected in triplicate by incubation with cationic liposomes (6 µl of FuGENE 6 and 1 µg of DNA/Transwell). Forty-eight hours later, the cells were exposed to IL-1{beta} or its vehicle for 8 or 24 h. In some experiments, an inhibitor of p38 MAPK or dexamethasone (100 nM) with or without mifepristone (RU486; 5 µM), a known GR antagonist, was added to the cell medium 1 h prior to exposure to IL-1{beta} or its vehicle. Cell extracts were prepared and analyzed for luciferase activity using a luminometer (Promega, Madison, WI) according to the manufacturer's instructions. Luciferase activity was corrected for total cellular protein and is reported as percent of the control cells (cells that were transfected but not treated with IL-1{beta}). Cells were also cotransfected with a {beta}-galactosidase plasmid, and {beta}-galactosidase activity was determined to verify that the efficiency of transfection was comparable within and between experiments.

Electrophoretic Mobility Shift Assay—Rat alveolar type II cells were plated in 24-mm filter insert culture dishes at a density of 5 x 106 cells/well and cultured for 4 days in an air-liquid interface. Cells were subjected to dexamethasone with or without IL-1{beta} and a p38 MAPK inhibitor for 5 h. For nuclear protein isolation, cells were washed three times with cold PBS and then harvested by scraping. Cells were collected by centrifugation, and the cell pellets were resuspended in lysis buffer (10 mM HEPES, pH 7.9, 10 mM KCl, 0.1 mM EDTA, 0.5 mM dithiothreitol, 0.4% Nonidet P-40, and 0.5 mM phenylmethylsulfonyl fluoride). After incubation on ice for 10 min, crude nuclei were isolated by centrifugation at 10,000 x g for 10 min at 4 °C. The supernatant was removed; 3 cell pellet volumes of high salt extraction buffer (20 mM HEPES, pH 7.9, 420 mM NaCl, 0.5 mM dithiothreitol, 1 mM EDTA, and 0.5 mM phenylmethylsulfonyl fluoride) were added; and the suspension was incubated on a rotary shaker for 30 min at 4 °C. The sample was centrifuged at 16,000 x g for 30 min at 4 °C; the supernatant (containing extracted nuclear proteins) was collected; the protein concentration was determined; and the lysate was stored at –70 °C until further use. Electrophoretic mobility shift assay was performed using a GRE consensus oligonucleotide probe (designed based on GenBankTM/EBI accession number AF081783 [GenBank] (26)) that was end-labeled with [{gamma}-32P]ATP (see Table I). After labeling, forward and reverse oligonucleotides were annealed slowly from 95 °C to room temperature. Nuclear protein (5 µg) was incubated with 100,000 cpm of 32P-labeled GRE consensus nucleotide for 20 min in binding buffer consisting of 10 mM Tris-HCl, pH 7.5, 1 mM MgCl2, 50 mM NaCl, 0.5 mM dithiothreitol, 0.5 mM EDTA, 4% glycerol, and 1 µg of poly(dI-dC). The specificity of the DNA/protein binding was determined by competition reactions in which a 100-fold molar excess of unlabeled GRE oligonucleotide was added. After incubation, the samples were analyzed by nondenaturing electrophoresis, and the bands were visualized by autoradiography.


View this table:
[in this window]
[in a new window]
  		TABLE I
Primers and probes used in this study

 
Primers and Probes—Real-time reverse transcription (RT)-PCR primers and probes (Table I) were designed using Primer Express software (PE-Applied Biosystems, Warrington, United Kingdom). The TaqMan probes were labeled with a fluorophore reporter dye (6-carboxyfluorescein) at the 5'-end and a Black Hole Quencher dye (Biosearch Technologies, Inc.) at the 3'-end.

Quantitative Real-time RT-PCR—Total RNA was extracted from rat or human ATII cells cultured for 4 days in an air-liquid interface using the RNeasy mini kit (Qiagen Inc.). One microgram of total RNA was reverse-transcribed using the Superscript first-strand synthesis system (Invitrogen). RT-PCRs were performed, and the results were analyzed using the ABI PRISM 7700 sequence detection system (PE-Applied Biosystems). Briefly, RT-PCR was carried out in a 25-µl reaction mixture containing 1x TaqMan Universal PCR Master Mix (PE-Biosystems, Foster City, CA), 10 pmol of primers, 5 pmol of TaqMan probe, and an equivalent of 100 ng of total RNA for 40 cycles at 95 °C for 15 s and 60 °C for 1 min. The number of cycles to threshold of fluorescence detection was normalized to the number of cycles to threshold of glyceraldehyde-3-phosphate dehydrogenase (GAPDH) for each sample tested. Results are expressed as a percentage of cDNA abundance compared with the control. The percentages were used for all statistical comparisons.

Statistics—All data are summarized as the mean ± S.D. One-way analysis of variance and Fisher's exact t test were used to compare experimental and control groups. A p value <0.05 was considered statistically significant.


   RESULTS
TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
DISCUSSION
 REFERENCES
 
IL-1{beta} Decreases Sodium Transport across Rat Lung Epithelial Cell Monolayers—We first determined whether IL-1{beta} affects the PD, TER, or apical Na+ uptake across primary cultures of rat ATII cell monolayers. Exposure to IL-1{beta} (0.01–10 ng/ml) significantly decreased the PD, an effect that was completely blocked by IL-1RA. IL-1{beta} had no effect on the measured TER, resulting in a significant reduction in the calculated transepithelial current (TEC) (Fig. 1, A–C). The IL-1{beta}-dependent reduction of the PD and TEC across ATII cell monolayers was observed as soon as 6 h after exposure to the cytokine (Fig. 1, D–F). IL-1{beta} affected both the basal and dexamethasone-dependent TECs across ATII cell monolayers independently of whether IL-1{beta} was tested on the apical or basal surface (Fig. 2, A and B). Furthermore, IL-1{beta} affected mostly the amiloride-sensitive fraction of TEC (Fig. 2C). Measurements of the PD and TER in ATII monolayers before and after addition of amiloride showed a decrease in the PD with no change in the TER (data not shown), indicating that the resistance of ATII monolayers is determined mostly by the tight junctions. We then hypothesized that the IL-1{beta}-mediated decrease in the calculated TEC is explained by a decrease in transepithelial ion transport. Therefore, we measured the effect of IL-1{beta} on both 22Na+ uptake across the apical membrane of rat ATII cells and 22Na+ transepithelial transport across the cell monolayers. Exposure to IL-1{beta} (10 ng/ml) for 6 h induced a significant decrease in the apical sodium uptake and the transepithelial 22Na+ transport across ATII monolayers, which were not further affected by addition of amiloride at a saturating concentration (10–4M) (Fig. 2, D and E). Taken together, the data indicate that IL-1{beta} significantly decreased the amiloride-sensitive fraction of the transepithelial sodium transport across rat ATII monolayers.



View larger version (56K):
[in this window]
[in a new window]
  		FIG. 1.
IL-1{beta} decreases the TEC across rat lung epithelial cell monolayers. A–C, IL-1{beta} causes a dose-dependent decrease in the transepithelial PD and TEC across primary cultures of polarized rat ATII cell monolayers. Rat ATII cell monolayers cultured in an air-liquid interface for 4 days were exposed to IL-1{beta} (10–3 to 10 ng/ml) or its vehicle for 24 h. The PD, TEC, and TER were measured with an epithelial ohmvoltmeter with Ag/AgCl electrodes. D–F, IL-1{beta} induces a time-dependent decrease in the PD and current across the apical membrane of primary cultures of polarized rat ATII cell monolayers. Rat ATII cell monolayers cultured in an air-liquid interface for 4 days were exposed to IL-1{beta} (10 ng/ml) or its vehicle for 1–24 h. The PD, TEC, and TER were measured as described above. For all experiments, control values for PD = 9.2 ± 1.3 mV, TER = 1.63 ± 0.18 kilo-ohms/cm2, and TEC = 5.8 ± 0.7 µA/cm2. The results are the mean ± S.D. of at least four experiments done in triplicate. *, p < 0.05 for monolayers exposed to IL-1{beta} vehicle.

 



View larger version (39K):
[in this window]
[in a new window]
  		FIG. 2.
IL-1{beta} decreases basal and dexamethasone-induced sodium transport across rat lung epithelial cell monolayers. A and B, IL-1{beta} causes a non-polarized decrease in the basal and dexamethasone-dependent TECs across primary cultures of polarized rat ATII cell monolayers. Rat ATII cell monolayers cultured in an air-liquid interface for 4 days were exposed for 6 h to IL-1{beta} (10 ng/ml) or its vehicle added on the apical or basolateral side or on both sides of the cell monolayer. The PD, TEC, and TER were measured with an epithelial ohmvoltmeter with Ag/AgCl electrodes. C, IL-1{beta} decreases the amiloride-sensitive fraction of the TEC of primary cultures of polarized rat ATII cell monolayers. Rat ATII cell monolayers cultured in an air-liquid interface for 4 days were exposed IL-1{beta} (10 ng/ml) or its vehicle for 6 h. Amiloride (10–4 M) was added for 15 min. The PD, TEC, and resistance were measured as described above. D and E, IL-1{beta} decreases the amiloride-sensitive fraction of sodium uptake across the apical membrane and sodium transport across monolayers of primary cultures of polarized rat ATII cells. Rat ATII cell monolayers cultured in an air-liquid interface for 4 days were exposed to IL-1{beta} (10 ng/ml) or its vehicle for 6 h. 22Na+ uptake and transepithelial 22Na+ transport were measured as described under "Experimental Procedures." In some experiments, amiloride (10–4 M) was added to the flux medium. For all experiments, control values for PD = 8.6 ± 1.1 mV, TER = 1.6 ± 0.15 kilo-ohms/cm2, TEC = 5.5 ± 0.6 µA/cm2, and 22Na flux = 76 ± 8 nmol/mg of protein/6 min. The results are the mean ± S.D. of at least four experiments done in triplicate. *, p < 0.05 for monolayers exposed to IL-1{beta} vehicle.

 
IL-1{beta} Decreases {alpha}ENaC Gene Expression in Rat and Human Lung Epithelial Cells—The next series of experiments was designed to determine whether IL-1{beta} alters {alpha}ENaC gene expression. Exposure to IL-1{beta} (0.1–10 ng/ml) for 6 h caused a dose-dependent decrease in basal {alpha}ENaC mRNA expression that was blocked by pretreatment with IL-1RA (Fig. 3A). IL-1{beta} also significantly decreased the dexamethasone-induced {alpha}ENaC mRNA levels (Fig. 3B). In parallel, we examined the effect of IL-1{beta} on the mRNA levels of the {beta}- and {gamma}-subunits of ENaC in both unstimulated and dexamethasone-stimulated cells. Quantitative real-time PCR analysis revealed that IL-1{beta} also caused a decrease in both basal and dexamethasone-stimulated {beta}ENaC and {gamma}ENaC mRNA levels (Fig. 3, C and D), with a greater effect on the {alpha}- and {gamma}-subunits.



View larger version (32K):
[in this window]
[in a new window]
  		FIG. 3.
IL-1{beta} decreases {alpha}ENaC gene expression in rat lung epithelial cell monolayers via a p38 MAPK-dependent mechanism. A, IL-1{beta} causes a dose-dependent decrease in {alpha}ENaC mRNA levels in primary cultures of polarized rat ATII cell monolayers. Rat ATII cell monolayers cultured in an air-liquid interface for 4 days were exposed to IL-1{beta} (10 ng/ml) or its vehicle for 6 h. {alpha}ENaC mRNA levels were measured in ATII cells by real-time RT-PCR and normalized to GAPDH mRNA levels. B–D, IL-1{beta} decreases the basal and dexamethasone-induced mRNA levels of {alpha}ENaC, {beta}ENaC, and {gamma}ENaC. {alpha}ENaC, {beta}ENaC, and {gamma}ENaC mRNA levels were measured as described for A. In some experiments, dexamethasone (Dex; 100 nM) was added to the culture medium at the same time as IL-1{beta} or its vehicle. E, IL-1{beta} decreases {alpha}ENaC mRNA abundance via a p38 MAPK-dependent mechanism. {alpha}ENaC mRNA levels were measured as described for A. In some experiments, PD98059 (an inhibitor of the kinase upstream of ERK1/2; 10 µM), SB202190 (an inhibitor of p38 MAPK; 10 µM), or SP600125 (an inhibitor of JNK; 10 µM) was added to the cell medium 1 h before the 6-h exposure to IL-1{beta} (10 ng/ml) or its vehicle. F, reduction in {alpha}ENaC mRNA expression by IL-1{beta} occurs at the transcriptional level and does not depend on the de novo synthesis of proteins. {alpha}ENaC mRNA levels were measured as described for A. In some experiments, either actinomycin D (Act D; 40 µM) or cycloheximide (CHX; 5 µM) was added to the cell medium 30 min before the 6-h exposure to IL-1{beta} (10 ng/ml) or its vehicle. For all experiments, the results are the mean ± S.D. of at least three experiments done in triplicate. *, p < 0.05 for monolayers exposed to IL-1{beta} vehicle; **, p < 0.05 for monolayers exposed to dexamethasone and IL-1{beta} vehicle.

 
Because the MAPKs have been shown to be downstream mediators of IL-1{beta} signaling (27, 28), ATII cells were preincubated with specific inhibitors of ERK1/2, p38, and JNK 1 h before addition of IL-1{beta}. SB202190 (a p38 MAPK inhibitor), but not the other MAPK inhibitors, blocked the IL-1{beta}-dependent decrease in {alpha}ENaC mRNA levels (Fig. 3E). To determine whether IL-1{beta} directly affects mRNA transcription, we then examined the effect of actinomycin D and cycloheximide on the IL-1{beta}-dependent decrease in {alpha}ENaC mRNA abundance by quantitative real-time PCR. The results showed that IL-1{beta} had a direct effect on {alpha}ENaC gene expression because its effect was blocked by pretreatment with actinomycin D, but was unaffected by pretreatment with cycloheximide (Fig. 3F).

Finally, the studies on the effect of IL-1{beta} on {alpha}ENaC gene expression were extended to primary cultures of human ATII cells because of possible differences in {alpha}ENaC gene regulation by IL-1{beta} between rodents and humans. IL-1{beta} caused a significant decrease in {alpha}ENaC mRNA levels in human lung epithelial cells, which was blocked by preincubation with SB212090, a p38 MAPK inhibitor (Fig. 4). Taken together, these experiments indicate that IL-1{beta} caused a decrease in basal and dexamethasone-dependent {alpha}ENaC gene expression via a p38 MAPK-dependent mechanism in both rat and human ATII cells.



View larger version (15K):
[in this window]
[in a new window]
  		FIG. 4.
IL-1{beta} decreases {alpha}ENaC mRNA levels in primary cultures of polarized human ATII cell monolayers via a p38 MAPK-dependent mechanism. Human ATII cell monolayers cultured in an air-liquid interface for 5 days were exposed to IL-1{beta} or its vehicle for 6 h. In some experiments, the p38 MAPK inhibitor SB202190 (10 µM) was added to the cell medium 1 h before the 6-h exposure to IL-1{beta} (10 ng/ml) or its vehicle. The results are the mean ± S.D. of three experiments done in duplicate. *, p < 0.05 for monolayers exposed to IL-1{beta} vehicle.

 
IL-1{beta} Decreases Total and Membrane {alpha}ENaC Protein Expression in Rat Lung Epithelial Cells—The next series of experiments were performed to determine the effect of IL-1{beta} on {alpha}ENaC protein levels in rat ATII cell monolayers. Exposure to IL-1{beta} (10 ng/ml) caused a significant decrease in both basal and dexamethasone-induced {alpha}ENaC protein expression (Fig. 5A). This effect was time-dependent and specific for IL-1{beta} because it was reversed by IL-1RA (Fig. 5, A and B). Furthermore, IL-1{beta} decreased {alpha}ENaC protein expression via a p38 MAPK-dependent mechanism (Fig. 5C). IL-1{beta} induced the phosphorylation of p38 MAPK and its downstream kinase MAPKAPK-2, an effect that was blocked by pretreatment with SB212090 in ATII cells (Fig. 5D).



View larger version (30K):
[in this window]
[in a new window]
  		FIG. 5.
IL-1{beta} decreases {alpha}ENaC total protein expression in polarized rat ATII cell monolayers. A, IL-1{beta} decreases basal and dexamethasone-induced {alpha}ENaC protein expression. Rat ATII cell monolayers cultured in an air-liquid interface for 4 days were exposed to IL-1{beta} (10 ng/ml) or its vehicle for 6 h with or with dexamethasone (Dex; 100 nM) or IL-1RA (10 µg/ml). {alpha}ENaC total protein expression was measured by Western blotting. One representative experiment is shown; three additional experiments gave comparable results. B, time-dependent effect of IL-1{beta} on {alpha}ENaC protein expression. Rat ATII cell monolayers cultured in an air-liquid interface for 4 days were exposed to IL-1{beta} (10 ng/ml) or its vehicle for 2, 6, and 24 h. {alpha}ENaC total protein expression was detected by Western blotting. One representative experiment is shown; three additional experiments gave comparable results. C, IL-1{beta} decreases {alpha}ENaC protein expression via a p38 MAPK-dependent mechanism. Rat ATII cell monolayers were cultured in an air-liquid interface for 4 days. In some experiments, the p38 MAPK inhibitor SB202190 (10 µM) was added to the cell medium 1 h before exposure to IL-1{beta} (10 ng/ml) or its vehicle for 6 h. {alpha}ENaC total protein expression was detected by Western blotting. One representative experiment is shown; three additional experiments gave comparable results. D, IL-1{beta} induces p38 MAPK and MAPKAPK-2 phosphorylation in primary cultures of rat ATII cells. Rat ATII cell monolayers cultured in an air-liquid interface for 4 days were exposed to IL-1{beta} (10 ng/ml) or its vehicle for 5, 10, 30, and 60 min. Total protein expression was determined by Western blotting. In some experiments, the p38 MAPK inhibitor SB202190 (10 µM) was added to the cell medium 1 h before exposure to IL-1{beta} or its vehicle. One representative experiment is shown; three additional experiments gave comparable results. For all experiments, densitometry analysis results are the mean ± S.D. of three experiments. *, p < 0.05 for monolayers exposed to IL-1{beta} vehicle.

 
The next series of experiments were designed to determine whether IL-1{beta} would decrease the expression of {alpha}ENaC protein on the apical membrane of rat ATII cell monolayers. IL-1{beta} caused a time-dependent decrease in both basal and dexamethasone-induced {alpha}ENaC expression on the apical membrane of rat ATII cells (Fig. 6, A and B). Taken together, these data demonstrate that IL-1{beta} decreased total and apical membrane {alpha}ENaC protein expression via a p38 MAPK-dependent mechanism.



View larger version (23K):
[in this window]
[in a new window]
  		FIG. 6.
IL-1{beta} decreases apical membrane {alpha}ENaC expression in polarized rat ATII cell monolayers. A, IL-1{beta} decreases basal {alpha}ENaC expression on the apical cell membrane of polarized rat ATII cell monolayers. Rat ATII cell monolayers cultured in an air-liquid interface for 4 days were exposed to IL-1{beta} (10 ng/ml) or its vehicle for 1, 4, and 6 h. {alpha}ENaC protein expression on the apical cell membrane was measured by cell-surface biotinylation as described under "Experimental Procedures." One representative experiment is shown; three additional experiments gave comparable results. B, IL-1{beta} decreases dexamethasone-induced {alpha}ENaC expression on the apical cell membrane of polarized rat ATII cell monolayers. Rat ATII cell monolayers cultured in an air-liquid interface for 4 days were exposed to dexamethasone for 12 h (100 nM) and then to IL-1{beta} (10 ng/ml) or its vehicle for 1, 4, and 6 h in the presence of dexamethasone (100 nM). {alpha}ENaC protein expression on the apical cell membrane was measured by cell-surface biotinylation as described "Experimental Procedures." One representative experiment is shown; three additional experiments gave comparable results. For all experiments, densitometry analysis results are the mean ± S.D. of three experiments. *, p < 0.05 for monolayers exposed to IL-1{beta} vehicle.

 
IL-1{beta} Inhibits {alpha}ENaC Promoter Activity by Decreasing GR Nuclear Translocation via a p38 MAPK-dependent Mechanism—To further understand the mechanism of IL-1{beta}-dependent down-regulation of {alpha}ENaC gene expression in lung epithelial cells, we measured the activity of the {alpha}ENaC promoter after exposure to IL-1{beta} in rat ATII cells. Luciferase assays were performed by transiently transfecting rat ATII cells with plasmid pGL-3 containing the luciferase gene subcloned downstream of the murine {alpha}ENaC promoter with or without a deletion in the GRE. IL-1{beta} decreased the dexamethasone-dependent {alpha}ENaC promoter activity by 90%. This effect was not observed in lung epithelial cells transiently transfected with a plasmid that did not respond to dexamethasone because of a deletion in the GRE (pGL3-basic/{alpha}mENaC{Delta}AVR-XhOI) (Fig. 7A). A comparable lack of response to dexamethasone was also observed upon pretreatment of the cell monolayers with mifepristone (RU486), a known GR antagonist, before exposing the cells to dexamethasone. Interestingly, IL-1{beta} did not further inhibit the dexamethasone-dependent {alpha}ENaC promoter activity in cells that had been pretreated with mifepristone (Fig. 7A). Pretreatment with the p38 MAPK inhibitor SB202190 (added 1 h before IL-1{beta}) reversed the IL-1{beta}-mediated inhibition of the dexamethasone-dependent {alpha}ENaC promoter activity in lung epithelial cells (Fig. 7B). Furthermore, the results of electrophoretic mobility shift assays with GRE consensus oligonucleotides demonstrated that IL-1{beta} decreased the nuclear translocation of the GR and its binding to the GRE. This effect was also blocked by SB202190 (Fig. 7, C and D). Taken together, these experiments indicate that IL-1{beta} decreased {alpha}ENaC promoter activity via a p38 MAPK-dependent mechanism.



View larger version (30K):
[in this window]
[in a new window]
  		FIG. 7.
IL-1{beta} inhibits {alpha}ENaC promoter activity in polarized rat ATII cell monolayers via a p38 MAPK-dependent mechanism. A, IL-1{beta} inhibits dexamethasone-dependent {alpha}ENaC promoter activity. Rat ATII cells were transiently transfected with a plasmid containing the luciferase gene under the control of the murine {alpha}ENaC promoter (pGL3-basic/{alpha}mENaC) or with a plasmid containing the luciferase gene under the control of the murine {alpha}ENaC promoter with a deletion in the GRE (pGL3-basic/{alpha}mENaC{Delta}AVR-XhOI). In contrast to pGL3-basic/{alpha}mENaC, pGL3-basic/{alpha}mENaC{Delta}AVR-XhOI was not responsive to dexamethasone. Forty-eight hours later, the cells were exposed to IL-1{beta} (10 ng/ml) or its vehicle in the presence of dexamethasone (Dex; 100 nM) for 8 h with or without mifepristone (RU486; 5 µM). The results are the mean ± S.D. of three experiments done in triplicate. *, p < 0.05 for monolayers exposed to IL-1{beta} vehicle. B, IL-1{beta} inhibits dexamethasone-dependent {alpha}ENaC promoter activity via a p38 MAPK-dependent mechanism. Rat ATII cells were transiently transfected with the pGL3-basic/{alpha}mENaC plasmid as described for A. The cells were exposed to IL-1{beta} (10 ng/ml) or its vehicle in the presence of dexamethasone (100 nM) for 8 h. The p38 MAPK inhibitor SB202190 (10 µM) or its vehicle was added in some experiments to the cell medium 1 h before exposure to IL-1{beta} or its vehicle. Control luciferase activity = 143.8 ± 12.6 relative light units (RLU)/µg of protein. The results are the mean ± S.D. of three experiments done in triplicate. *, p < 0.05 for monolayers exposed to IL-1{beta} vehicle. The base-line luciferase activity values obtained after transfection with the empty vector were within the range of the background values measured in cells that were not transfected. C and D, IL-1{beta} inhibits GR nuclear translocation via a p38 MAPK-dependent mechanism. Rat ATII cell monolayers cultured in an air-liquid interface for 4 days were exposed to IL-1{beta} (10 ng/ml) for 6 h in the presence of dexamethasone (100 nM). In some experiments, SB202190 (10 µM) was added to the cell medium 1 h before exposure to IL-1{beta} or its vehicle. GR binding to GRE was examined by electrophoretic mobility shift assay. Five micrograms of nuclear protein were incubated with a 32P-labeled GRE consensus oligonucleotide. In some reactions, the mixture also contained a 100-fold excess of the unlabeled GRE consensus oligonucleotide (COLD PROBE). Densitometry analysis results are the mean ± S.D. of three experiments. *, p < 0.05 for monolayers exposed to IL-1{beta} vehicle.

 
IL-1{beta} Decreases {alpha}ENaC Protein and Gene Expression Independently of {alpha}v{beta}6 Integrin Activation of TGF-{beta}—We have previously reported that {alpha}v{beta}6 integrin activates TGF-{beta} in epithelial cells (29) and that active TGF-{beta}1 decreases {alpha}ENaC gene and protein expression in rat and human ATII cell monolayers (30). The next series of experiments were designed to elucidate the potential role of {alpha}v{beta}6 integrin or TGF-{beta} in the IL-1{beta}-dependent down-regulation of {alpha}ENaC. Quantification of {alpha}ENaC mRNA was performed in rat alveolar type II cells stimulated with IL-1{beta} after preincubation with {alpha}v{beta}6 integrin-blocking antibody; a TGF-{beta} type I, II, and III receptor-blocking agent (decorin); or a soluble chimeric TGF-{beta} type II receptor. Quantitative real-time PCR revealed that {alpha}v{beta}6 integrin-blocking antibody, decorin, and the soluble chimeric TGF-{beta} type II receptor did not prevent the IL-1{beta}-dependent inhibition of basal or dexamethasone-induced {alpha}ENaC gene expression (Fig. 8, A and B). At the protein level, Western blotting confirmed that blocking {alpha}v{beta}6 integrin or TGF-{beta} did not prevent the decrease in {alpha}ENaC protein abundance by IL-1{beta} (Fig. 8C). Taken together, these results show that the effect of IL-1{beta} on {alpha}ENaC protein and gene expression was {alpha}v{beta}6 integrin/TGF-{beta}-independent.



View larger version (21K):
[in this window]
[in a new window]
  		FIG. 8.
IL-1{beta}-dependent decrease in {alpha}ENaC gene and protein expression is independent of {alpha}v{beta}6 integrin and TGF-{beta} activation. A and B, IL-1{beta} decreases basal and dexamethasone-dependent {alpha}ENaC mRNA expression independently of {alpha}v{beta}6 integrin or TGF-{beta} activation. Primary cultures of polarized rat ATII cell monolayers maintained in an air-liquid interface for 4 days were exposed to IL-1{beta} (10 ng/ml) or its vehicle for 6 h with or without {alpha}v{beta}6 integrin-blocking antibody (100 µg/ml), decorin (10 µg/ml), or the soluble chimeric TGF-{beta} type II receptor (TGF{beta}-scRII; 20 µg/ml). {alpha}ENaC mRNA levels were measured in ATII cells by real-time RT-PCR and normalized to GAPDH mRNA levels. The results are the mean ± S.D. of at least three experiments done in triplicate. *, p < 0.05 for monolayers exposed to IL-1{beta} vehicle. C, IL-1{beta} decreases {alpha}ENaC protein levels independently of {alpha}v{beta}6 integrin or TGF-{beta} activation. Primary cultures of polarized rat ATII cell monolayers maintained in an air-liquid interface for 4 days were exposed to IL-1{beta} (10 ng/ml) or its vehicle for 6 h with or without {alpha}v{beta}6 integrin-blocking antibody (100 µg/ml) or an antibody against the three isoforms of TGF-{beta} (10 µg/ml). {alpha}ENaC total protein expression was detected by Western blotting. One representative experiment is shown; three additional experiments gave comparable results. Densitometry analysis results are the mean ± S.D. of three experiments. *, p < 0.05 for monolayers exposed to IL-1{beta} vehicle.

 
IL-1{beta} Does Not Affect Na+-K+-ATPase Gene or Protein Expression in Rat Lung Epithelial Cells—Because Na+-K+-ATPase is critical for establishing the gradient for net sodium transport across tight epithelia (31, 32), we examined the effect of IL-1{beta} on the mRNA and protein expression of the {alpha}1- and {beta}1-subunits of Na+-K+-ATPase. Real-time PCR analysis showed that IL-1{beta} (10 ng/ml, 6-h exposure) did not affect Na+-K+-ATPase {alpha}1- and {beta}1-subunit mRNA expression (Fig. 9A). Similarly, we found that IL-1{beta} (10 ng/ml) had no effect on {alpha}1- and {beta}1-subunit protein expression at 6 and 24 h (Fig. 9, B and C). These results indicate that the main effect of IL-1{beta} on sodium transport across the distal lung epithelium occurred through inhibition of the expression and function of apical ENaC.



View larger version (32K):
[in this window]
[in a new window]
  		FIG. 9.
IL-1{beta} does not affect Na+-K+-ATPase {alpha}1- and {beta}1 -subunit gene or total protein expression in rat lung epithelial cell monolayers. A, IL-1{beta} does not affect Na+-K+-ATPase {alpha}1- and {beta}1-subunit mRNA levels in primary cultures of polarized rat ATII cell monolayers. Rat ATII cell monolayers cultured in an air-liquid interface for 4 days were exposed to IL-1{beta} (10 ng/ml) or its vehicle for 6 h. Na+-K+-ATPase {alpha}1- and {beta}1-subunit mRNA levels were measured in ATII cells by real-time RT-PCR and normalized to GAPDH mRNA levels. For all experiments, the results are the mean ± S.D. of at least three experiments done in triplicate. B, IL-1{beta} does not affect Na+-K+-ATPase {alpha}1-subunit protein expression. Rat ATII cell monolayers cultured in an air-liquid interface for 4 days were exposed to IL-1{beta} (10 ng/ml) or its vehicle for 6 and 24 h. Na+-K+-ATPase total {alpha}1-subunit protein expression was measured by Western blotting. One representative experiment is shown; three additional experiments gave comparable results. C, IL-1{beta} does not affect Na+-K+-ATPase {beta}1-subunit protein expression. Rat ATII cell monolayers cultured in an air-liquid interface for 4 days were exposed to IL-1{beta} (10 ng/ml) or its vehicle for 6 and 24 h. Na+-K+-ATPase total {beta}1-subunit protein expression was measured by Western blotting. One representative experiment is shown; three additional experiments gave comparable results. For all experiments, densitometry analysis results are the mean ± S.D. of three experiments.

 

   DISCUSSION
TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
REFERENCES
 
IL-1{beta} has been shown to affect the function of the lung epithelial barrier by increasing protein paracellular permeability and causing surfactant abnormalities (33, 34), both characteristic features of ALI. However, the effect of IL-1{beta} on alveolar ion transport is still unknown. We therefore examined whether IL-1{beta} would affect sodium transport across the distal lung epithelium, where most of the vectorial fluid clearance from the airspace occurs.

We found that IL-1{beta} decreased the TEC across ATII cell monolayers in a time- and dose-dependent manner, predominantly affecting the amiloride-sensitive alveolar transepithelial sodium transport. Our results are in accordance with those of previous studies showing that, in other epithelia such as the distal colon and the renal collecting duct, IL-1{beta} inhibits apical sodium absorption (9, 10). In addition, IL-1{beta} has also been shown to reduce amiloride-sensitive short circuit current in normal human bronchial epithelial cells (11). Interestingly, in contrast to the previously described effect of TGF-{beta} on the TEC across alveolar type II cell monolayers, which occurs exclusively on the basolateral side (30), the effect of IL-1{beta} occurred independently on the side of cytokine application. The lack of sidedness might be explained by a transient IL-1{beta}-induced increase in paracellular permeability that could cause the cytokine to diffuse across the leaky cell monolayer.

The most common amiloride-sensitive sodium channel on the apical surface of lung epithelial cells is ENaC, formed by three homologous subunits (35). This ion channel has been shown to be critical in the absorption of salt and fluid by lung epithelial cells and has an important role in keeping the airspace dry to allow physiological gas exchange (36–38). We found that IL-1{beta} caused a decrease in ENaC mRNA expression in both rat and human epithelial cells. Moreover, IL-1{beta} caused a non-coordinated down-regulation of ENaC subunits, affecting the {alpha}- and {gamma}-subunits more than the {beta}-subunit. Other studies have also shown differential regulation of the three ENaC subunits. IL-4 has been shown to cause a greater decrease in {gamma}ENaC mRNA levels in human bronchial epithelial cells (39), whereas tumor necrosis factor-{alpha} and hypoxia cause a greater decrease in the {beta}ENaC and {gamma}ENaC mRNA levels in the distal colon and alveolar epithelium, respectively (9, 40).

Under physiological conditions, the {alpha}ENaC gene is positively regulated by several factors, including, but not limited to, cortisol (41, 42), cAMP (43, 44), aldosterone (17, 45), and insulin (46, 47). Among them, cortisol plays a critical role in maintaining lung fluid balance at birth (48) and during adult life (41) via an increase in ENaC gene expression in lung epithelial cells. In particular, cortisol and other synthetic glucocorticoids such as dexamethasone increase mRNA expression of all three ENaC subunits in several epithelia, including the lung (49–51) and renal collecting duct (52). Furthermore, glucocorticoids increase {alpha}ENaC mRNA expression in the lung (53). The effect of the glucocorticoids on {alpha}ENaC gene expression is mediated by translocation of the glucocorticoid-GR complex to the nucleus and its binding to the GRE on the {alpha}ENaC promoter (51).We found that IL-1{beta} decreased dexamethasone-dependent {alpha}ENaC mRNA and total protein expression. Our results are consistent with previous in vitro studies showing that IL-1{alpha} and IL-1{beta} inhibit GR nuclear translocation and dexamethasone-induced gene transcription (54, 55). Furthermore, after dexamethasone stimulation, IL-1{beta} decreased {alpha}ENaC total protein expression less than apical plasma membrane {alpha}ENaC protein expression, suggesting that IL-1{beta} might also modulate ENaC trafficking to the apical membrane of alveolar epithelial cells. In vivo, the effect of IL-1{beta} on the vectorial transport of sodium across the distal lung epithelium is still unclear. We have previously reported that the release of IL-1{beta} in the distal airspaces of the lung after the onset of hemorrhage prevents the cAMP-mediated up-regulation of alveolar liquid clearance in rats (56). The effect of IL-1{beta} is mediated by an NO-dependent mechanism (57). Taken together, these studies and our study show that IL-1{beta} affects ion transport in the distal lung epithelium directly by inhibiting ENaC biosynthesis and indirectly by preventing the cAMP-mediated up-regulation of this transport.

By which mechanism does IL-1{beta} affect sodium absorption in the distal lung epithelium? IL-1{beta} binds to its membrane IL-1{beta} type I receptor, triggering the activation of several signaling pathways such as the MAPKs. We found that inhibition of the p38 MAPK signaling pathway completely prevented the IL-1{beta}-mediated reduction in both {alpha}ENaC gene and protein expression in ATII cells. Indeed, IL-1{beta} inhibited the dexamethasone-dependent {alpha}ENaC promoter activity via a decrease in GR/GRE binding by a p38 MAPK-dependent mechanism. These results are in accordance with those of a previous study showing that IL-1{alpha} inhibits the nuclear translocation of the GR and its DNA binding in mouse fibroblast cells transfected with a GR-mediated reporter gene construct (54).

We have recently reported that active TGF-{beta}1 is a critical mediator of ALI (24) and causes a decrease in {alpha}ENaC protein and gene expression in rat and human ATII cell monolayers (30). Furthermore, we have previously found that {alpha}v{beta}6 integrin, expressed in conducting airways and alveoli (58–60), activates endogenous latent TGF-{beta}1 in epithelial cells (29). In addition, several studies have shown that {alpha}v{beta}6 integrin expression is markedly up-regulated in epithelial cells of multiple epithelial organs, including the lung, in response to acute and chronic inflammation and in cancer (58, 60, 61). Therefore, we sought to determine whether the IL-1{beta}-dependent down-regulation of {alpha}ENaC would be mediated by {alpha}v{beta}6 integrin or TGF-{beta}. In fact, the effect of IL-1{beta} on {alpha}ENaC protein and gene expression was {alpha}v{beta}6 integrin/TGF-{beta}-independent. These results suggest that IL-1{beta} and TGF-{beta} may have independent roles in the down-regulation of ENaC and the reduction of sodium transport in the distal lung epithelium via distinct molecular pathways that could be additive in inhibiting the removal of alveolar edema from airspaces in ALI patients. Furthermore, our results indicate that IL-1{beta} does not affect gene and protein expression of Na+-K+-ATPase in ATII cells. However, these data do not exclude that IL-1{beta} might modulate Na+-K+-ATPase pump activity, possibly by affecting the trafficking of the channel subunits to the basolateral membrane. A complete understanding of the possible effect of IL-1{beta} on the expression and function of Na+-K+-ATPase will require further studies.

In summary, the results of this study indicate that IL-1{beta} causes a reduction in sodium transport across ATII cells. This effect is attributable in large part to a decrease in apical membrane {alpha}ENaC expression in lung epithelial cells resulting from p38 MAPK-mediated inhibition of the {alpha}ENaC promoter activity and to an alteration in ENaC trafficking to the plasma membrane. Because a reduction in net alveolar fluid clearance has been associated with increased respiratory failure and higher mortality in patients with ALI (2, 3) and given that IL-1{beta} is one of the most bioactive cytokines present in the distal airspaces of patients with ALI (4–6), IL-1{beta} may be an important mediator of impaired fluid clearance in patients with ALI.


   FOOTNOTES
 
* This work was supported by National Institutes of Health Grants R01GM62188 and P50HL074005 (to J.-F. P.) and Grant HL51854 (to M. A. M.) and by a fellowship grant from the Cystic Fibrosis Research, Inc. (to J. R.). The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact. Back

{boxs} The on-line version of this article (available at http://www.jbc.org) contains supplemental Fig. A. Back

¶¶ To whom correspondence should be addressed: Dept. of Anesthesia, San Francisco General Hospital, Rm. 3C-38, 1001 Potrero Ave., San Francisco, CA 94110. Tel.: 415-206-8163; Fax: 415-206-6014; E-mail: pittetj{at}anesthesia.ucsf.edu.

1 The abbreviations used are: ALI, acute lung injury; IL, interleukin; ENaC, epithelial sodium channel; ATII, alveolar epithelial type II; MAPK, mitogen-activated protein kinase; ERK, extracellular signal-regulated kinase; JNK, c-Jun N-terminal kinase; GR, glucocorticoid receptor; IL-1RA, IL-1{beta} receptor antagonist; TGF-{beta}, transforming growth factor-{beta}; MAPKAPK, MAPK-activated protein kinase; GRE, glucocorticoid response element; PBS, phosphate-buffered saline; TER, transepithelial electrical resistance; PD, potential difference; RT, reverse transcription; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; TEC, transepithelial current. Back


   ACKNOWLEDGMENTS
 
We thank André Dagenais for the generous gift of {alpha}ENaC promoter-luciferase constructs and Marybeth Howard for careful review of the manuscript.



   REFERENCES
TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 

  1. Ware, L. B., and Matthay, M. A. (2000) N. Engl. J. Med. 342, 1334–1349[Free Full Text]
  2. Ware, L. B., and Matthay, M. A. (2001) Am. J. Respir. Crit. Care Med. 163, 1376–1383[Abstract/Free Full Text]
  3. Matthay, M. A., and Wiener-Kronish, J. P. (1990) Am. Rev. Respir. Dis. 142, 1250–1257[Medline] [Order article via Infotrieve]
  4. Pugin, J., Verghese, G., Widmer, M. C., and Matthay, M. A. (1999) Crit. Care Med. 27, 304–312[CrossRef][Medline] [Order article via Infotrieve]
  5. Olman, M. A., White, K. E., Ware, L. B., Simmons, W. L., Benveniste, E. N., Zhu, S., Pugin, J., and Matthay, M. A. (2004) J. Immunol. 172, 2668–2677[Abstract/Free Full Text]
  6. Pugin, J., Ricou, B., Steinberg, K. P., Suter, P. M., and Martin, T. R. (1996) Am. J. Respir. Crit. Care Med. 153, 1850–1856[Abstract]
  7. Lee, Y. M., Hybertson, B. M., Cho, H. G., Terada, L. S., Cho, O., Repine, A. J., and Repine, J. E. (2000) Am. J. Physiol. 279, L75–L80
  8. Geiser, T., Jarreau, P. H., Atabai, K., and Matthay, M. A. (2000) Am. J. Physiol. 279, L1184–L1190
  9. Barmeyer, C., Amasheh, S., Tavalali, S., Mankertz, J., Zeitz, M., Fromm, M., and Schulzke, J.-D. (2004) Biochem. Biophys. Res. Commun. 317, 500–507[CrossRef][Medline] [Order article via Infotrieve]
  10. Zeidel, M. L., Brady, H. R., and Kohan, D. E. (1991) Am. J. Physiol. 261, F1013–F1016
  11. Gray, T., Coakley, R., Hirsh, A., Thornton, D., Kirkham, S., Koo, J.-S., Burch, L., Boucher, R., and Nettesheim, P. (2004) Am. J. Physiol. 286, L320–330
  12. Cui, C.-H., Adachi, T., Oyamada, H., Kamada, Y., Kuwasaki, T., Yamada, Y., Saito, N., Kayaba, H., and Chihara, J. (2002) Am. J. Respir. Cell Mol. Biol. 27, 329–335[Abstract/Free Full Text]
  13. Furuichi, S., Hashimoto, S., Gon, Y., Matsumoto, K., and Horie, T. (2002) Respirology 7, 193–200[CrossRef][Medline] [Order article via Infotrieve]
  14. Hashimoto, S., Matsumoto, K., Gon, Y., Nakayama, T., Takeshita, I., and Horie, T. (1999) Am. J. Respir. Crit. Care Med. 159, 634–640[Abstract/Free Full Text]
  15. Suzuki, S., Zuege, D., and Berthiaume, Y. (1995) Am. J. Physiol. 268, L983–L990
  16. Huang, X., Wu, J., Spong, S., and Sheppard, D. (1998) J. Cell Sci. 111, 2189–2195[Abstract]
  17. Duc, C., Farman, N., Canessa, C. M., Bonvalet, J. P., and Rossier, B. C. (1994) J. Cell Biol. 127, 1907–1921[Abstract/Free Full Text]
  18. Dobbs, L. G. (1990) Am. J. Physiol. 258, L134–L147
  19. Dobbs, L. G., Gonzalez, R., and Williams, M. C. (1986) Am. Rev. Respir. Dis. 134, 141–145[Medline] [Order article via Infotrieve]
  20. Fang, X., Song, Y., Zemans, R., Hirsch, J., and Matthay, M. A. (2004) Am. J. Physiol. 287, L104–L110
  21. Ware, L. B., Wang, Y., Fang, X., Warnock, M., Sakuma, T., Hall, T. S., and Matthay, M. (2002) Lancet 360, 619–620[CrossRef][Medline] [Order article via Infotrieve]
  22. Tiballi, R., He, X., Zarins, L., Revankar, S., and Kauffman, C. (1995) J. Clin. Microbiol. 33, 915–917[Abstract]
  23. Mairbaurl, H., Wodopia, R., Eckes, S., Schulz, S., and Bartsch, P. (1997) Am. J. Physiol. 273, L797–L806
  24. Pittet, J.-F., Griffiths, M. J., Geiser, T., Kaminski, N., Dalton, S. L., Huang, X., Brown, L. A., Gotwals, P. J., Koteliansky, V. E., Matthay, M. A., and Sheppard, D. (2001) J. Clin. Investig. 107, 1537–1544[Medline] [Order article via Infotrieve]
  25. Alvarez de la Rosa, D., Li, H., and Canessa, C. M. (2002) J. Gen. Physiol. 119, 427–442[Abstract/Free Full Text]
  26. Otulakowski, G., Rafii, B., Bremner, H. R., and O'Brodovich, H. (1999) Am. J. Respir. Cell Mol. Biol. 20, 1028–1040[Abstract/Free Full Text]
  27. Towne, J. E., Garka, K. E., Renshaw, B. R., Virca, G. D., and Sims, J. E. (2004) J. Biol. Chem. 279, 13677–13688[Abstract/Free Full Text]
  28. Kumar, A., Middleton, A., Chambers, T. C., and Mehta, K. D. (1998) J. Biol. Chem. 273, 15742–15748[Abstract/Free Full Text]
  29. Munger, J. S., Huang, X., Kawakatsu, H., Griffiths, M. J., Dalton, S. L., Wu, J., Pittet, J.-F., Kaminski, N., Garat, C., Matthay, M. A., Rifkin, D. B., and Sheppard, D. (1999) Cell 96, 319–328[CrossRef][Medline] [Order article via Infotrieve]
  30. Frank, J., Roux, J., Kawakatsu, H., Su, G., Dagenais, A., Berthiaume, Y., Howard, M., Canessa, C. M., Fang, X., Sheppard, D., Matthay, M. A., and Pittet, J.-F. (2003) J. Biol. Chem. 278, 43939–43950[Abstract/Free Full Text]
  31. Adir, Y., Factor, P., Dumasius, V., Ridge, K. M., and Sznajder, J. I. (2003) Am. J. Respir. Crit. Care Med. 168, 1445–1448[Abstract/Free Full Text]
  32. Dada, L. A., Chandel, N. S., Ridge, K. M., Pedemonte, C., Bertorello, A. M., and Sznajder, J. I. (2003) J. Clin. Investig. 111, 1057–1064[CrossRef][Medline] [Order article via Infotrieve]
  33. Hybertson, B. M., Lee, Y. M., Cho, H. G., Cho, O. J., and Repine, J. E. (2000) Inflammation 24, 289–303[CrossRef][Medline] [Order article via Infotrieve]
  34. Benito, E., and Bosch, M. A. (1998) Mol. Cell. Biochem. 189, 169–176[CrossRef][Medline] [Order article via Infotrieve]
  35. Canessa, C. M., Merillat, A. M., and Rossier, B. C. (1994) Am. J. Physiol. 267, C1682–C1690
  36. McDonald, F. J., Yang, B., Hrstka, R. F., Drummond, H. A., Tarr, D. E., McCray, P. B., Jr., Stokes, J. B., Welsh, M. J., and Williamson, R. A. (1999) Proc. Natl. Acad. Sci. U. S. A. 96, 1727–1731[Abstract/Free Full Text]
  37. Barker, P. M., Nguyen, M. S., Gatzy, J. T., Grubb, B., Norman, H., Hummler, E., Rossier, B., Boucher, R. C., and Koller, B. (1998) J. Clin. Investig. 102, 1634–1640[Medline] [Order article via Infotrieve]
  38. Hummler, E., Barker, P., Gatzy, J., Beermann, F., Verdumo, C., Schmidt, A., Boucher, R., and Rossier, B. C. (1996) Nat. Genet. 12, 325–328[CrossRef][Medline] [Order article via Infotrieve]
  39. Galietta, L. J., Pagesy, P., Folli, C., Caci, E., Romio, L., Costes, B., Nicolis, E., Cabrini, G., Goossens, M., Ravazzolo, R., and Zegarra-Moran, O. (2002) J. Immunol. 168, 839–845[Abstract/Free Full Text]
  40. Planes, C., Blot-Chabaud, M., Matthay, M. A., Couette, S., Uchida, T., and Clerici, C. (2002) J. Biol. Chem. 277, 47318–47324[Abstract/Free Full Text]
  41. Norlin, A., Baines, D. L., and Folkesson, H. G. (1999) J. Physiol. (Lond.) 519, 261–272[Abstract/Free Full Text]
  42. Jain, L., Chen, X.-J., Ramosevac, S., Brown, L. A., and Eaton, D. C. (2001) Am. J. Physiol. 280, L646–L658
  43. Snyder, P. M. (2000) J. Clin. Investig. 105, 45–53[Medline] [Order article via Infotrieve]
  44. Chen, X.-J., Eaton, D. C., and Jain, L. (2002) Am. J. Physiol. 282, L609–L620
  45. Lingueglia, E., Renard, S., Waldmann, R., Voilley, N., Champigny, G., Plass, H., Lazdunski, M., and Barbry, P. (1994) J. Biol. Chem. 269, 13736–13739[Abstract/Free Full Text]
  46. Blazer-Yost, B. L., Liu, X., and Helman, S. I. (1998) Am. J. Physiol. 274, C1373–C1379
  47. Shimkets, R. A., Lifton, R., and Canessa, C. M. (1998) Proc. Natl. Acad. Sci. U. S. A. 95, 3301–3305[Abstract/Free Full Text]
  48. Baines, D. L., Folkesson, H. G., Norlin, A., Bingle, C. D., Yuan, H. T., and Olver, R. E. (2000) J. Physiol. (Lond.) 522, 147–157[Abstract/Free Full Text]
  49. Tchepichev, S., Ueda, J., Canessa, C., Rossier, B. C., and O'Brodovich, H. (1995) Am. J. Physiol. 269, C805–C812
  50. Renard, S., Voilley, N., Bassilana, F., Lazdunski, M., and Barbry, P. (1995) Pfluegers Arch. Eur. J. Physiol. 430, 299–307[CrossRef][Medline] [Order article via Infotrieve]
  51. Dagenais, A., Denis, C., Vives, M. F., Girouard, S., Masse, C., Nguyen, T., Yamagata, T., Grygorczyk, C., Kothary, R., and Berthiaume, Y. (2001) Am. J. Physiol. 281, L217–L230
  52. Itani, O. A., Cornish, K. L., Liu, K. Z., and Thomas, C. P. (2003) Am. J. Physiol. 284, F778–F787
  53. Stokes, J. B., and Sigmund, R. D. (1998) Am. J. Physiol. 274, C1699–C1707
  54. Wang, X., Wu, H., and Miller, A. H. (2004) Mol. Psychiatry 9, 65–75[CrossRef][Medline] [Order article via Infotrieve]
  55. Webster, J. C., Oakley, R. H., Jewell, C. M., and Cidlowski, J. A. (2001) Proc. Natl. Acad. Sci. U. S. A. 98, 6865–6870[Abstract/Free Full Text]
  56. Laffon, M., Lu, L. N., Modelska, K., Matthay, M. A., and Pittet, J.-F. (1999) Am. J. Physiol. 277, L760–L768
  57. Pittet, J.-F., Lu, L. N., Morris, D. G., Modelska, K., Welch, W. J., Carey, H. V., Roux, J., and Matthay, M. A. (2001) J. Immunol. 166, 6301–6310[Abstract/Free Full Text]
  58. Breuss, J. M., Gallo, J., DeLisser, H. M., Klimanskaya, I. V., Folkesson, H. G., Pittet, J.-F., Nishimura, S. L., Aldape, K., Landers, D. V., Carpenter, W., Gillett, N., Sheppard, D., Matthay, M. A., Albelda, S. M., Kramer, R. H., and Pytela, R. (1995) J. Cell Sci. 108, 2241–2251[Abstract]
  59. Breuss, J. M., Gillett, N., Lu, L., Sheppard, D., and Pytela, R. (1993) J. Histochem. Cytochem. 41, 1521–1527[Abstract]
  60. Weinacker, A., Ferrando, R., Elliott, M., Hogg, J., Balmes, J., and Sheppard, D. (1995) Am. J. Respir. Cell Mol. Biol. 12, 547–556[Abstract]
  61. Bates, R. C., Bellovin, D. I., Brown, C., Maynard, E., Wu, B., Kawakatsu, H., Sheppard, D., Oettgen, P., and Mercurio, A. M. (2005) J. Clin. Investig. 115, 339–347[CrossRef][Medline] [Order article via Infotrieve]

Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 J. Am. Soc. Nephrol.Home page
F. Aldehni, M. Spitzner, J. R. Martins, R. Barro-Soria, R. Schreiber, and K. Kunzelmann
Bestrophin 1 Promotes Epithelial-to-mesenchymal Transition of Renal Collecting Duct Cells
J. Am. Soc. Nephrol., July 1, 2009; 20(7): 1556 - 1564.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Cell Mol. Bio.Home page
F. A. Bozza, A. M. Shah, A. S. Weyrich, and G. A. Zimmerman
Amicus or Adversary: Platelets in Lung Biology, Acute Injury, and Inflammation
Am. J. Respir. Cell Mol. Biol., February 1, 2009; 40(2): 123 - 134.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
D. W. Chang, S. Hayashi, S. A. Gharib, T. Vaisar, S. T. King, M. Tsuchiya, J. T. Ruzinski, D. R. Park, G. Matute-Bello, M. M. Wurfel, et al.
Proteomic and Computational Analysis of Bronchoalveolar Proteins during the Course of the Acute Respiratory Distress Syndrome
Am. J. Respir. Crit. Care Med., October 1, 2008; 178(7): 701 - 709.
[Abstract] [Full Text] [PDF]

Home page
 ThoraxHome page
J A Frank, J Francois-Pittet, and M A Matthay
Authors' reply
Thorax, August 1, 2008; 63(8): 751 - 751.
[Full Text] [PDF]

Home page
 Mol. Cell. Biol.Home page
K. Namekata, C. Harada, K. Kohyama, Y. Matsumoto, and T. Harada
Interleukin-1 Stimulates Glutamate Uptake in Glial Cells by Accelerating Membrane Trafficking of Na+/K+-ATPase via Actin Depolymerization
Mol. Cell. Biol., May 15, 2008; 28(10): 3273 - 3280.
[Abstract] [Full Text] [PDF]

Home page
 Circ. Res.Home page
M. T. Ganter, J. Roux, B. Miyazawa, M. Howard, J. A. Frank, G. Su, D. Sheppard, S. M. Violette, P. H. Weinreb, G. S. Horan, et al.
Interleukin-1{beta} Causes Acute Lung Injury via {alpha}v{beta}5 and {alpha}v{beta}6 Integrin-Dependent Mechanisms
Circ. Res., April 11, 2008; 102(7): 804 - 812.
[Abstract] [Full Text] [PDF]

Home page
 PhysiologyHome page
H. A. Drummond, S. C. Grifoni, and N. L. Jernigan
A New Trick for an Old Dogma: ENaC Proteins as Mechanotransducers in Vascular Smooth Muscle
Physiology, February 1, 2008; 23(1): 23 - 31.
[Abstract] [Full Text] [PDF]

Home page
 Chem SensesHome page
P. L. Wall and L. P. McCluskey
Rapid Changes in Gustatory Function Induced by Contralateral Nerve Injury and Sodium Depletion
Chem Senses, February 1, 2008; 33(2): 125 - 135.
[Abstract] [Full Text] [PDF]

Home page
 ThoraxHome page
J A Frank, J-F Pittet, C Wray, and M A Matthay
Protection from experimental ventilator-induced acute lung injury by IL-1 receptor blockade
Thorax, February 1, 2008; 63(2): 147 - 153.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
K. S. Abayasiriwardana, D. Barbone, K.-U. Kim, C. Vivo, K. K. Lee, T. B. Dansen, A. E. Hunt, G. I. Evan, and V. C. Broaddus
Malignant mesothelioma cells are rapidly sensitized to TRAIL-induced apoptosis by low-dose anisomycin via Bim
Mol. Cancer Ther., October 1, 2007; 6(10): 2766 - 2776.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
G. Konopka, J. Tekiela, M. Iverson, C. Wells, and S. A. Duncan
Junctional Adhesion Molecule-A Is Critical for the Formation of Pseudocanaliculi and Modulates E-cadherin Expression in Hepatic Cells
J. Biol. Chem., September 21, 2007; 282(38): 28137 - 28148.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
J. W. Lee, X. Fang, G. Dolganov, R. D. Fremont, J. A. Bastarache, L. B. Ware, and M. A. Matthay
Acute Lung Injury Edema Fluid Decreases Net Fluid Transport across Human Alveolar Epithelial Type II Cells
J. Biol. Chem., August 17, 2007; 282(33): 24109 - 24119.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Cell Mol. Bio.Home page
L. Wang, J. A. Bastarache, N. Wickersham, X. Fang, M. A. Matthay, and L. B. Ware
Novel Role of the Human Alveolar Epithelium in Regulating Intra-Alveolar Coagulation
Am. J. Respir. Cell Mol. Biol., April 1, 2007; 36(4): 497 - 503.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Cell Mol. Bio.Home page
M. A. Matthay and H. G. Folkesson
Reduction of Alveolar Epithelial Ion and Fluid Transport by Inflammatory Mediators
Am. J. Respir. Cell Mol. Biol., March 1, 2007; 36(3): 389 - 389.
[Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
T. Li, S. Varadarajulu, L. L. Beard, J. Yun, and H. G. Folkesson
A Noninflammatory Interleukin-1beta Fragment Stimulates Fetal Lung Fluid Absorption in Guinea Pigs
J. Pharmacol. Exp. Ther., February 1, 2007; 320(2): 877 - 884.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Lung Cell. Mol. Physiol.Home page
A. Dagenais, R. Frechette, M.-E. Clermont, C. Masse, A. Prive, E. Brochiero, and Y. Berthiaume
Dexamethasone inhibits the action of TNF on ENaC expression and activity
Am J Physiol Lung Cell Mol Physiol, December 1, 2006; 291(6): L1220 - L1231.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Heart Circ. Physiol.Home page
S. C. Grifoni, K. P. Gannon, D. E. Stec, and H. A. Drummond
ENaC proteins contribute to VSMC migration
Am J Physiol Heart Circ Physiol, December 1, 2006; 291(6): H3076 - H3086.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
N. Jin, N. Kolliputi, D. Gou, T. Weng, and L. Liu
A Novel Function of Ionotropic {gamma}-Aminobutyric Acid Receptors Involving Alveolar Fluid Homeostasis
J. Biol. Chem., November 24, 2006; 281(47): 36012 - 36020.
[Abstract] [Full Text] [PDF]

Home page
 J. Am. Soc. Nephrol.Home page
E. Babilonia, D. Li, Z. Wang, P. Sun, D.-H. Lin, Y. Jin, and W.-H. Wang
Mitogen-Activated Protein Kinases Inhibit the ROMK (Kir 1.1)-Like Small Conductance K Channels in the Cortical Collecting Duct
J. Am. Soc. Nephrol., October 1, 2006; 17(10): 2687 - 2696.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Lung Cell. Mol. Physiol.Home page
M. T. Ganter, L. B. Ware, M. Howard, J. Roux, B. Gartland, M. A. Matthay, M. Fleshner, and J.-F. Pittet
Extracellular heat shock protein 72 is a marker of the stress protein response in acute lung injury
Am J Physiol Lung Cell Mol Physiol, September 1, 2006; 291(3): L354 - L361.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Cell Mol. Bio.Home page
H. G. Folkesson and M. A. Matthay
Alveolar Epithelial Ion and Fluid Transport: Recent Progress
Am. J. Respir. Cell Mol. Biol., July 1, 2006; 35(1): 10 - 19.
[Full Text] [PDF]

Home page
 Am. J. Physiol. Lung Cell. Mol. Physiol.Home page
T. Li and H. G. Folkesson
RNA interference for {alpha}-ENaC inhibits rat lung fluid absorption in vivo
Am J Physiol Lung Cell Mol Physiol, April 1, 2006; 290(4): L649 - L660.
[Abstract] [Full Text] [PDF]

Home page
 J. Neurophysiol.Home page
L. Liu, T. M. Yang, W. Liedtke, and S. A. Simon
Chronic IL-1beta Signaling Potentiates Voltage-Dependent Sodium Currents in Trigeminal Nociceptive Neurons
J Neurophysiol, March 1, 2006; 95(3): 1478 - 1490.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
S. C. Wesselkamper, L. M. Case, L. N. Henning, M. T. Borchers, J. W. Tichelaar, J. M. Mason, N. Dragin, M. Medvedovic, M. A. Sartor, C. R. Tomlinson, et al.
Gene Expression Changes during the Development of Acute Lung Injury Role of Transforming Growth Factor {beta}
Am. J. Respir. Crit. Care Med., December 1, 2005; 172(11): 1399 - 1411.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Supplemental Data
Right arrow All Versions of this Article:
280/19/18579    most recent
M410561200v2
M410561200v1
Right arrow Submit a Letter to Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Roux, J.
Right arrow Articles by Pittet, J.-F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Roux, J.
Right arrow Articles by Pittet, J.-F.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 All ASBMB Journals   Molecular and Cellular Proteomics 
 Journal of Lipid Research   ASBMB Today 
Copyright © 2005 by the American Society for Biochemistry and Molecular Biology.
Advertisement
spacer
Advertisement
Advertisement